EPA:ALIKO - Euronext Paris - Matif - FR00140048X2 - Common Stock - Currency: EUR
EPA:ALIKO (5/8/2025, 7:00:00 PM)
1.56
+0.02 (+1.3%)
The current stock price of ALIKO.PA is 1.56 EUR. In the past month the price increased by 11.43%. In the past year, price increased by 11.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 28.2 | 206.87B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 71.18 | 172.45B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 38.91 | 137.55B | ||
2M6.DE | MEDTRONIC PLC | 15.79 | 95.77B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 20.84 | 52.90B | ||
BOX.DE | BECTON DICKINSON AND CO | 11.99 | 42.93B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 29.24 | 39.54B | ||
DC4.DE | DEXCOM INC | 51.58 | 29.53B | ||
1PHIA.MI | KONINKLIJKE PHILIPS NV | 16.09 | 21.02B | ||
PHIA.AS | KONINKLIJKE PHILIPS NV | 15.97 | 20.42B | ||
PHI1.DE | KONINKLIJKE PHILIPS NV | 15.48 | 20.23B | ||
BIM.PA | BIOMERIEUX | 30.18 | 13.79B |
Ikonisys SA specializes in the design, manufacture, and distribution of cellular diagnosis applications for cancer, genetic diseases, and fertility problems. The company is headquartered in Paris, Ile-De-France and currently employs 10 full-time employees. The company went IPO on 2021-07-19. The firm offers cell diagnostic products in the fields of cancer diagnosis, detection of genetic disorders, and fertility testing. The company utilizes advanced molecular and immunological markers, Ikoniscope robotic components, software engine, image acquisition, digital microscope and cell detection to design and deliver accurate and reliable detection of rare cells. The company includes clinical diagnostic applications for the diagnosis of different types of cancer, including bladder (oncoFISH bladder), breast (oncoFISH her2), cervical (oncoFISH cervical), prostate (oncoFISH PTEN), lung (oncoFISH ALK) and a variety of hematological cancers utilizing the Explorer applications.
IKONISYS SA
62 Rue De Caumartin, Paris 9
Paris ILE-DE-FRANCE FR
Employees: 10
The current stock price of ALIKO.PA is 1.56 EUR. The price increased by 1.3% in the last trading session.
The exchange symbol of IKONISYS SA is ALIKO and it is listed on the Euronext Paris - Matif exchange.
ALIKO.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALIKO.PA and the average price target is 4.18 EUR. This implies a price increase of 168.08% is expected in the next year compared to the current price of 1.56. Check the IKONISYS SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IKONISYS SA (ALIKO.PA) has a market capitalization of 21.51M EUR. This makes ALIKO.PA a Nano Cap stock.
IKONISYS SA (ALIKO.PA) currently has 10 employees.
IKONISYS SA (ALIKO.PA) has a support level at 1.56 and a resistance level at 1.6. Check the full technical report for a detailed analysis of ALIKO.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALIKO.PA does not pay a dividend.
IKONISYS SA (ALIKO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
ChartMill assigns a technical rating of 10 / 10 to ALIKO.PA. When comparing the yearly performance of all stocks, ALIKO.PA is one of the better performing stocks in the market, outperforming 81.39% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to ALIKO.PA. Both the profitability and financial health of ALIKO.PA have multiple concerns.
Over the last trailing twelve months ALIKO.PA reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -6.92% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.87% | ||
ROE | -14.41% | ||
Debt/Equity | 0.1 |
ChartMill assigns a Buy % Consensus number of 87% to ALIKO.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.